Hanson Pharmaceuticals (03692.HK) to issue 2.3 million shares under restricted share unit plans
On April 19, GLONGHUI | Hanson Pharmaceuticals (03692.HK) announced that it will issue 2.3 million shares of the company on April 19, 2024 in accordance with the restricted share unit plan approved and adopted by the company on May 27, 2019.
Is Hansoh Pharmaceutical Group Company Limited (HKG:3692) Trading At A 23% Discount?
Key Insights The projected fair value for Hansoh Pharmaceutical Group is HK$20.45 based on 2 Stage Free Cash Flow to Equity Hansoh Pharmaceutical Group's HK$15.66 share price signals that it might b
Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug
Hansoh Pharmaceutical Group (HKG:3692) said Chinese regulator NMPA has granted clinical trial approval for the group's HS10504 tablets, being developed to treat advanced, non-small-cell lung cancer, according to a Wednesday filing with the Hong Kong bourse.
Hanson Pharmaceuticals (03692.HK): HS-10504 tablets received clinical trial notice
Gelonghui, April 3 | Hanson Pharmaceutical (03692.HK) announced that the Class 1 new drug HS-10504 tablets independently developed by the company's subsidiary Jiangsu Hausen Pharmaceutical Group Co., Ltd. and Shanghai Hanson Biomedical Technology Co., Ltd. have obtained a clinical trial notice approved and issued by the China National Drug Administration to treat advanced non-small cell lung cancer. The specific indications are to be determined after clinical trials.
Hansoh Pharmaceutical Group Company Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Investors in Hansoh Pharmaceutical Group Company Limited (HKG:3692) had a good week, as its shares rose 4.2% to close at HK$15.48 following the release of its yearly results. It looks like a cre
Citibank: Maintaining Hanson Pharmaceuticals (03692)'s “Buy” Rating and Raising the Target Price to HK$28
Citigroup said it raised Hanson Pharmaceuticals (03692)'s revenue forecasts for this year and next year by 8.6% and 2.7%, respectively, while earnings per share estimates were raised by 29.5% and 15.4%.
CICC: Maintaining Hanson Pharmaceuticals' (03692) “outperforming the industry” rating, the target price was raised to HK$17.81
The Zhitong Finance App learned that CICC released a research report saying that maintaining Hanson Pharmaceuticals (03692)'s “outperforming the industry” rating, due to the fact that the cooperative down payment bookkeeping section will be confirmed in 2024 and the bank expects the company's three fees to be well controlled, the 24-year revenue and net profit forecast to be raised 2.0%/11.0% to RMB 11,566/3.43 billion yuan, and introduced a 25-year profit forecast of 3.56 billion yuan for the first time. The target price increased by 27.2% to HK$17.81 as the company's pipeline of innovative drugs entered the harvest period. According to the report, the company's revenue from innovative drugs and cooperative products in 2023 was 6.87 billion yuan, accounting for
Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
HANSOH PHARMA To Go Ex-Dividend On June 19th, 2024 With 0.1422 HKD Dividend Per Share
March 27th - $HANSOH PHARMA(03692.HK)$ is trading ex-dividend on June 19th, 2024. Shareholders of record on June 20th, 2024 will receive 0.1422 HKD dividend per share on July 17th, 2024. The ex-di
BOC International: Maintaining Hanson Pharmaceuticals (03692)'s “Neutral” Rating Target Price of HK$16
BOC International raised Hanson Pharmaceuticals (03692) 2024-25E revenue forecast by 7%-14%.
Hanson Pharmaceuticals (03692.HK)'s total revenue in 2023 broke 10 billion, and net profit increased 26.9% year-on-year
On March 26, 2024, Hanson Pharmaceuticals (03692.HK) announced its 2023 annual results. During the reporting period, it achieved operating income of about RMB 10.104 billion (same unit), an increase of about 7.7% over the same period last year, and net profit of about RMB 3.278 billion, an increase of about 26.9% over the same period last year. The report shows that in 2023, Hanson Pharmaceuticals' revenue from innovative drugs and cooperative products was about 6.865 billion yuan, an increase of about 37.1% over the previous year, accounting for 67.9% of total revenue. Innovative drugs have become the core driving force for performance growth. Behind leading innovation strength is continuous investment in R&D, 202
Changes in Hong Kong stocks | Hanson Pharmaceuticals (03692) rose more than 5% last year's revenue surpassed 10 billion dollars, and the share of revenue from innovative products increased by nearly 68%
Hanson Pharmaceuticals (03692) rose more than 5%. As of press release, it rose 5.24% to HK$15.66, with a turnover of HK$38.288 million.
Hanson Pharmaceuticals (03692) announced 2023 results, net profit of $3.277.5 billion, a year-on-year increase of 26.85%, final interest of HK14.22 cents per share
Hanson Pharmaceuticals (03692) announced its 2023 results, with revenue of about 10.104 billion yuan, an increase of 7.7% year-on-year...
HANSOH PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
[Special Offer V] Deng Shengxing: Investors are still cautious about entering the market while waiting for the results of the Savings Bureau's interest rate discussions
Jinwu Financial News | The Hang Seng Index closed at 16,720 on Friday (15th), down 240 points or 1.42%. The market traded 139.086 billion yuan throughout the day. The China Index fell 86 points, or 1.46%, to 5820; the Science Index closed down 53 points, or 1.5%, to 3,549. Tencent (00700) fell 1.9% to 283.8 yuan, with the highest transaction reaching 8.266 billion yuan. Yao Ming Biotech (02269) dropped another 10.2%, making it the worst performing blue chip. Today, only 11 blue chips recorded increases, with Zijin Mining (02899) performing best with a 2.6% increase. The Dow closes on Friday (15th)
Biotheus Expanded Their Partnership With Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates
ZHUHAI, China, March 15, 2024 /PRNewswire/ -- On March 14, 2024, Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inf
Changes in Hong Kong stocks | Hanson Pharmaceuticals (03692) reversed the market by more than 5% and signed a licensing agreement with Promex, and the company obtained exclusive global license from HS-20117
Hanson Pharmaceuticals (03692) reversed the market and rose by more than 5%. As of press release, it rose 4.65% to HK$15.74, with a turnover of HK$40,882,900.
Hanson Pharmaceuticals (03692) has signed a license agreement with Pumis to use HS-20117 for the development, production and commercialization of bispecific antibody conjugate products
Hanson Pharmaceuticals (03692) announced that on March 14, 2024, Hanson (Shanghai) Health Technology Co., Ltd., a wholly-owned subsidiary of the company, signed a license agreement with the licensee Pumis Biotechnology (Zhuhai) Co., Ltd. (Pumis).
Hanson Pharmaceuticals (03692.HK) signs licensing agreement with Promise Biotechnology (Zhuhai)
Gelonghui, March 14, 丨 Hanson Pharmaceutical (03692.HK) announced that on March 14, 2024, Hanson (Shanghai) Health Technology Co., Ltd. (licensee), a wholly-owned subsidiary of the company, signed a license agreement with Promise Biotechnology (Zhuhai) Co., Ltd. According to the license agreement, the licensee obtained an exclusive license from Pumis to develop, produce and commercialize HS-20117 (introduction project name PM1080) for bispecific antibody conjugate products (ADC products) worldwide, and has the right to further sub-license. The licensee will pay the down payment and ADC-based products
Hanson Pharmaceuticals (03692.HK) plans to hold a board meeting on March 26 to approve annual results
Glonghui, March 14 | Hanson Pharmaceuticals (03692.HK) announced that a board meeting will be held on March 26, 2024 (Tuesday) to consider and approve the company's and its subsidiaries' annual results and proposed final dividends (if any) for the year ended 31 December 2023, and to deal with other matters.
No Data